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Summary
The patient affected by epilepsy related to brain tu-
mours presents certain features linked to the summa-
tion of his cancer-related problems and his epilepsy-re-
lated problems. Furthermore, epilepsy in brain tumour
patients is often refractory to pharmacological treat-
ments and can complicate the therapeutic management
of these patients due to the increased incidence of
pharmacological interactions and adverse effects. 
Analysis of the data in the literature suggests that it is
opportune, when planning antiepileptic therapy in
these cases, to choose the new-generation drugs, as
these show a lower incidence of pharmacological inter-
actions with the therapies used in brain tumour pa-
tients (chemotherapies, radiotherapy and support ther-
apies), have fewer adverse effects, and have less im-
pact on neuropsychological functions, all factors that
strongly influence the patient’s quality of life. 
Of the new antiepileptic drugs, the following seem to be
promising in the treatment of cancer-related epilepsy:
oxcarbazepine, topiramate and levetiracetam (the latter
as an add-on therapy). The pharmacokinetic features of
these drugs, their effectiveness in controlling seizures,
and the reduced incidence of adverse effects make
them useful in this particular group of patients.
KEY WORDS: adverse effects, AEDs, brain tumours, epilepsy, inter-
actions.
Introduction
In spite of the considerable progress made in diagnos-
tics and in the fields of chemo- and radiotherapy, in the
ambit of therapies for primitive brain tumours, palliative
treatment of symptoms continues to be the key medical
intervention for improving quality of life. The most com-
mon symptom in patients with brain tumours is epilep-
sy: it is the presentation symptom in 20-40% of cases,
and will occur subsequently in 20-45% of the remaining
cases (1-4). Overall, the incidence of epilepsy in brain
tumours, considering all histological types and sites,
ranges from 35 to 90% (2,5,6). The patient affected by
epilepsy related to brain tumours presents certain fea-
tures linked to the summation of his cancer-related
problems and his epilepsy-related problems. Indeed,
during the course of his disease, a cancer patient un-
dergoes many treatments, pharmacological (chemother-
apy and support therapy) surgical, and radiological; he
may present neurological difficulties attributable to the
tumour and psychological difficulties linked to the fact of
having a disease with a probably unfavourable progno-
sis. Added to this, he has to deal with his epilepsy, which
necessitates recourse to other pharmacological treat-
ments (antiepileptic drugs, AEDs), and also live with the
unpredictability of seizures, and the psychological dis-
tress caused by this diagnosis. 
Epilepsy in brain tumour patients is often refractory to
pharmacological therapies, both for reasons linked to
the tumour itself, and because of poor efficacy of the
drugs as a result of pharmacological interactions. Fur-
thermore, the pathophysiological mechanisms underly-
ing the epileptic seizures in patients with brain tumours
are still unclear (7), whereas the correlations with sev-
eral other factors, such as the histology of the tumour,
its site, and the patient’s age at tumour onset, seem to
be better understood. The incidence of epilepsy at on-
set of tumour is inversely correlated with the degree of
malignancy of the tumour: higher (ranging from 65 to
95% of cases) in those with a low degree of malignan-
cy (astrocytomas, oligodendrogliomas, WHO grade I
and II mixed astrocytomas and meningiomas) and low-
er (15-25% of cases) in malignant gliomas (5). A young
age at tumour onset is more frequent in slowly-growing
tumours and is associated with a higher incidence of
epilepsy. A very important feature determining the ap-
pearance, or non appearance, of seizures is the site of
the tumour: seizures are more frequent in supratentori-
al (as opposed to subtentorial) tumours whose site is
cortical or superficial (as opposed to deep seated). The
presence of epileptic seizures as an onset symptom of
the tumour seems to be a favourable prognostic factor:
this may be due to earlier diagnosis, to better surgical
access (more superficial sites), or to the presence of
more favourable histotypes (slowly-growing tumours).
As regards the type of epileptic seizures occurring in
brain tumour patients, they are, in most cases, simple-
partial or complex seizures; partial seizures with sec-
ondary generalization are also frequent, but their focal
onset is often difficult to detect clinically because of the
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suddenness of the generalization phenomena due to
the rapid diffusion of the epileptogenic discharge from
the focus ipsilateral to the lesion, which can be detect-
ed only on EEG. Primary generalized seizures are more
rare in patients with brain tumours.
Epilepsy and brain tumour implies the summation of
many drug therapies, making the therapeutic manage-
ment of affected patients particularly difficult. There are
two fundamental reasons for this: i) an increased proba-
bility of pharmacological interactions, and ii) a higher in-
cidence of adverse effects of the various drug treat-
ments. Therefore, the neuro-oncologist, who has to
make the therapeutic choices, must be equipped with in-
depth knowledge of the problems linked to the pharma-
cological interactions and the adverse effects of the
drugs used.
Pharmacological interactions
A pharmacological interaction occurs when one drug
modifies the activity of another, increasing or reducing
its effects (8). It is positive, if it increases the efficacy of
the other drug, or negative, if it increases adverse ef-
fects or reduces its efficacy. There are two types of inter-
action between drugs. 
Pharmacodynamic interactions occur between drugs
that have similar or different mechanisms of action.
They take place at cellular level (either at the site of ac-
tion of the drug or elsewhere) and they are not associat-
ed with alterations of the plasma levels of the two drugs.
At present, they can be demonstrated only by means of
in vitro studies.
Pharmacokinetic interactions occur when one drug in-
terferes with the distribution in the organism of another
drug, altering its concentration at the site of action. This
results in changes in the plasma levels of both drugs
and of their metabolites. These interactions can occur at
any stage during the drug’s passage through the organ-
ism.
In the drug absorption phase, some drugs can alter the
absorption of others. For example, antacids reduce ab-
sorption of phenytoin, phenobarbital, carbamazepine
and gabapentin, by reducing gastric acidity and forming
complexes that are insoluble with them.
The drug distribution phase concerns the binding with
the plasma proteins and the free fractions of the active
drug. For example, concomitant administration of
phenytoin and valproic acid causes release of the
phenytoin from the protein bond; this leads to increased
phenytoin concentration and possible toxicity. Other
AEDs, such as lamotrigine, levetiracetam, topiramate
and vigabatrin, on the other hand, do not show a signif-
icant degree of protein bonding and are thus not prone
to this type of interaction. The active metabolite of oxcar-
bazepine shows a low degree of plasma protein binding,
making clinically significant competitive binding unlikely
at this level (9). 
During the elimination phase, a drug is eliminated from
the organism through renal excretion (as in the case of
vigabatrin, gabapentin, levetiracetam and felbamate), or
hepatic excretion. Elimination by the hepatic excretion
route, which is associated with the most clinically signif-
icant pharmacological interactions, may occur by means
of glucuronidation (as in the case of lamotrigine) or by
means of biotransformation of the drug mediated by
CYP isoenzymes belonging to the cytochrome P450
system. These isoenzymes catalyze the oxidation reac-
tions both of drugs and of endogenously produced sub-
stances, and their function can be modified by the con-
comitant administration of other substances (6). This
means that P450-enzyme-inducing drugs provoke faster
elimination of a second concomitantly administered drug
and thus a reduction of its efficacy, or at least of its con-
centration at the site of action. Since induction of the
CYP enzymes involves the synthesis of numerous pro-
teins (the same CYP enzymes), it can be days or weeks
before the effects on the pharmacokinetics appear.
CYP-enzyme-inhibiting drugs decrease the metabolism
of the second drug, increasing the risk of toxicity and of
the appearance of adverse effects. Of the AEDs, pheno-
barbital, primidone, carbamazepine and phenytoin act
as enzyme inducers, and thus enhance the metabolism
of corticosteroids (drugs routinely administered to pa-
tients with brain tumours) and of many chemotherapeu-
tic agents, including nitrosoureas, paclitaxel, cyclophos-
phamide, etoposide, topotecan, irinotecan, thiotepa,
adriamycin and methotrexate. This means that the ad-
ministered doses of these drugs could be inadequate,
and therefore less effective (1,8,10) (Table I). On the
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Table I - Anti-epileptic drugs reduce the activity of chemotherapeutic drugs.
Phenobarbital Phenytoin Carbamazepine
Cyclophosphamide Busulfan Methotrexate
Ifosfamide Methotrexate Vincristine
Thiotepa Vincristine Paclitaxel
Nitrosoureas Paclitaxel 9-aminocamptothecin
Methotrexate Irinotecan Teniposide
Vincristine Topotecan
Paclitaxel 9-aminocamptothecin
9-aminocamptothecin Teniposide
Teniposide
Doxorubicin
Procarbazine
Tamoxifen
(Source: ref.s 1,11,13)
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other hand, many chemotherapeutic agents, too, are in-
ducers of the CYP enzymes and can therefore alter the
efficacy or increase the toxicity of many AEDs adminis-
tered concomitantly (Tables II and III). There are, to
date, no data in the literature suggesting that the new
AEDs interfere with anti-tumour drugs (8).
Adverse effects
The adverse effects of a drug can be divided into three
types: i) idiosyncratic toxicity, which is dose-independ-
ent, unpredictable, and usually manifests itself in the
early stages of consumption of the drug; ii) acute toxic
effects, which are dose-dependent, very frequent, and
can occur throughout the course of treatment with the
drug (these effects are often due to pharmacokinetic
modifications induced by concomitant therapies), and
iii) chronic toxic effects, which instead arise after
months or years of treatment, are linked to the total
quantity of the drug consumed, are specific for each
drug, and can even appear at therapeutic dosages. 
Adverse effects of AEDs are more frequent in patients
with tumour-related epilepsy than in the rest of the
epileptic population (1,6,8); a recent meta-analysis (1)
in fact showed the appearance of adverse effects se-
vere enough to warrant suspension or modification of
the AED therapy in 24% of patients affected by tumour-
related epilepsy, as opposed to 0.5-12% of patients
without tumour. In particular, many AEDs, in addition to
the idiosyncratic, haematological, and systemic toxicity
effects, also have effects on the central nervous system
(CNS), which can strongly impact on the patient’s qual-
ity of life, make it difficult to assess correctly the re-
sponse to chemotherapy, and even mimic a progres-
sion of the tumour (11). A recent study showed that can-
cer patients who used carbamazepine, phenobarbital,
valproic acid and phenytoin showed worse cognitive
performances, with the exception of verbal memory,
than those who did not use them (7). It is, on the other
hand, probable (although there are no studies confirm-
ing this) that the new AEDs could have less frequent
and milder effects on cognitive function. Every AED is
associated with certain adverse effects, but some of
these assume particular significance in the cancer pa-
tient:
1. Phenobarbital seems to be associated with the
worst cognitive profile (sedation, behavioural prob-
lems, cognitive deficits, depressed mood) (7), and its
use is thus not recommended in patients with brain tu-
mour and cognitive deficits (11). It can also cause
megaloblastic anaemia and scapular-humeral peri-
arthritis: the latter often causes pain and functional im-
potence, which can aggravate the tumour-related dis-
ability. 
2. Carbamazepine can cause dizziness, diplopia and
sedation, whereas its most feared idiosyncratic effect,
albeit rare, is haematological toxicity; it can also cause,
just at the start of treatment, a mild and non-progressive
leucopenia, which does not necessitate suspension of
the drug.
3. Phenytoin rarely gives rise to idiosyncratic reac-
tions; it can cause agranulocytosis (which does re-
quire suspension of the drug) and acute encephalopa-
thy with psychological and neurological problems that,
in the absence of the classic signs of toxicity, can
seem to suggest a progression of the tumour. Com-
bined use of phenytoin or carbamazepine during radio-
therapy seems to be associated with a higher risk of
developing severe cutaneous reactions (even
Stevens-Johnson syndrome), a risk that must be taken
into account by physicians prescribing these drugs to
neuro-oncological patients about to undergo radiother-
apy (12,13).
4. Valproic acid can, in some cases, cause acute en-
cephalopathy whose symptoms may suggest a pro-
gression of the tumour. It can induce coagulation
deficits and thrombocytopenia (and thus worsen the
thrombocytopenia caused by the chemotherapeutic
agents). Increased haematological toxicity has also
been reported in combined therapy with valproic acid
and nitrosoureas (14).
5. Oxcarbazepine does not significantly alter cognitive
function (15); in some cases it even seems to improve
psychomotor functions, in particular, attention and man-
ual writing speed (16). The most frequent CNS-related
adverse effects, usually only moderate, are somno-
lence, headache and dizziness. Although oxcar-
bazepine therapy has been associated with hypona-
traemia, this is usually asymptomatic and does not ne-
cessitate suspension of the drug (17).
6. Topiramate can cause problems with language and
memory. In particular, one double-blind study of healthy
subjects showed a global deterioration of cognitive func-
tions, especially language and memory, but not of motor
performances (18). Conversely, a study in patients with
epilepsy showed that topiramate administered as an
The pharmacological management of epilepsy in brain tumours
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Table II - Chemotherapeutic drugs reduce the activity of an-
ti-epileptic drugs.
Phenytoin Valproic acid Carbamazepine
Bleomycin Methotrexate Cisplatin
Nitrosoureas Cisplatin Adriamycin
Cisplatin Adriamycin
Etoposide
Dacarbazine
Adriamycin
Carboplatin
Vinblastin
Methotrexate
(Source: ref. 1)
Table III - Chemotherapeutic drugs increase the toxicity of
anti-epileptic drugs.
Valproic acid Phenytoin
Cisplatin Fluorouracil
Nitrosoureas Tegafur
Tamoxifen
(Source: ref. 1)
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add-on therapy to carbamazepine was well tolerated
and did not produce appreciable cognitive adverse ef-
fects (19).
7. The most frequent adverse effects of lamotrigine are
CNS-related (headache, diplopia, nausea, ataxia, dizzi-
ness), but it can also cause rashes, eosinophilia and
Stevens-Johnson syndrome (20).
8. Vigabatrin, gabapentin and levetiracetam are not me-
tabolized by oxidation or conjugation: therefore they
show little or no interaction with other drugs. Vigabatrin,
however, can cause sedation, depressed mood and
psychoses (21), as well as severe visual disorders.
Gabapentin has few adverse effects (22), but its effica-
cy in controlling seizures has not, to date, been proven.
Levetiracetam appears to be well tolerated, showing
good efficacy and few adverse effects, but it can cause
aggressive behaviours and agitation (23). 
In short, all the GABAergic drugs (phenobarbital, benzo-
diazepine, vigabatrin, tiagabine and topiramate) have
sedative effects and can induce depression; valproic
acid and lamotrigine, on the other hand, have antide-
pressant properties (11). In addition, phenobarbital,
phenytoin and carbamazepine are osteopenic, and thus
associated with an increased risk of fractures, particular-
ly of the hip and heel, whereas valproic acid is associat-
ed with reduced bone density (24).
Choosing the antiepileptic drug
The question of when to start antiepileptic therapy in
patients with tumour-related epilepsy is highly contro-
versial: in the USA, treatment is, in most cases, begun
after a single seizure, whereas in Europe there is no
common line of conduct; however, since patients with
brain tumour are considered to be at a high risk of re-
current seizures, it is considered necessary (contrary to
the recommendations in non tumour-related epilepsy)
to initiate antiepileptic therapy immediately after the first
seizure (11). Finally, as regards the type of drug to use,
it is recommended, as in traditional antiepileptic thera-
py, to begin with a monotherapy and, in the light of what
we have said above, to choose those new AEDs (oxcar-
bazepine, topiramate, lamotrigine) that are poor en-
zyme inducers, that have prevalently renal excretion, a
low degree of plasma protein binding and a mild ad-
verse effect profile, and that have already been ap-
proved by the Food and Drug Administration and by the
Italian Health Ministry for use in monotherapy. Should a
polytherapy be required, recent literature data (25,26)
confirm the need to use AEDs that are poor enzyme in-
ducers, such as the ones mentioned above, in combi-
nation with levetiracetam. 
Concluding remarks
In the patient with tumour-related epilepsy, the choice of
the best AED to use must be made bearing in mind both
the other therapies already in use (with a view to
achieving the best possible balance between efficacy
and adverse effects), and the impact on neuropsycho-
logical functions, which may be particularly vulnerable
in this group of patients. The ultimate aim must there-
fore be to guarantee and conserve a good quality of life,
while still exploiting as fully as possible all the available
therapies.
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